paramyxovirus
heterogen
group
virus
caus
varieti
clinic
diseas
human
anim
bird
illustr
tabl
shall
examin
detail
structur
properti
import
human
virus
group
name
measl
respiratori
syncyti
viru
rsv
mump
parainfluenza
virus
iv
brief
envelop
negativestrand
ribovirus
helic
symmetri
fig
genom
paramyxovirus
singl
neg
strand
rna
molecular
weight
approxim
x
contain
gene
code
six
known
viru
specif
protein
h
n
haemagglutininneuraminidas
f
fusion
matrix
protein
associ
lipid
membran
typic
paramyxoviru
hn
f
glycoprotein
see
constitut
surfac
spike
see
fig
typic
paramyxovirus
nonglycosyl
matrix
protein
underli
viral
membran
f
protein
form
proteolyt
cleavag
larger
precursor
glycosyl
polypeptid
f
three
protein
l
np
togeth
rna
form
nucleoprotein
core
virion
l
protein
may
constitut
viru
rna
transcriptas
enzym
whose
templat
genom
rna
complex
np
point
view
strategi
antivir
vaccin
rna
transcriptas
enzym
antigen
tabl
h
n
f
protein
respect
import
infect
cell
paramyxoviru
protein
synthes
mrna
speci
complementari
genom
appear
monocistron
two
major
size
class
mrna
detecteda
class
contain
mrna
speci
l
protein
class
contain
least
five
mrna
speci
summari
see
ball
et
al
gener
strategi
replic
typic
neg
strand
rna
viru
see
chapter
although
whether
precis
detail
differ
rsv
measl
mump
must
await
studi
viru
like
measl
belong
paramyxoviru
group
roughli
spheric
envelop
rnacontain
viru
nm
diamet
fig
intern
nucleocapsid
surround
lipid
envelop
approx
nm
thick
situat
outer
glycoprotein
virion
nucleocapsid
flexibl
helic
structur
rna
backbon
cover
protein
subunit
rna
approxim
x
mw
would
code
capac
least
protein
major
protein
viru
np
addit
polymeras
p
protein
thought
close
link
rna
function
rnatranscriptas
complex
membran
protein
anoth
major
constitu
virion
assum
contribut
structur
integr
viru
locat
insid
lipid
envelop
two
glycoprotein
spike
present
larger
hn
ha
na
activ
smaller
glycoprotein
f
involv
haemolyt
cell
fuse
activ
heppertz
et
al
narus
et
al
orvel
herder
compan
rima
et
al
viru
therefor
typic
properti
paramyxoviru
group
compar
member
group
rather
littl
known
detail
biochemistri
molecular
biolog
viru
recent
studi
merz
et
al
investig
intracellular
mump
virusspecif
polypeptid
synthesi
pulseand
pulsechaselabel
radioact
amino
acid
sugar
major
polypeptid
seen
sdspolyacrylamid
gel
np
k
mw
p
mw
mw
nonstructur
polypeptid
mw
also
present
infect
cell
lysat
hn
mw
glycopolypeptid
detect
glucosamineand
mannoselabel
infect
cell
mw
speci
incorpor
precursor
seen
pulselabel
infect
cell
lysat
glycopolypeptid
vanish
chase
interv
concomit
appear
two
glycopolypeptid
mw
mw
repres
f
subunit
f
glycoprotein
immunolog
data
confirm
related
mw
glycopolypeptid
f
glycoprotein
identifi
precursor
fo
f
precursor
glycopolypeptid
seen
cell
infect
fuse
nonfus
strain
viru
fo
process
complet
f
glycoprotein
infect
thu
mump
virusinfect
cell
contain
seven
virusspecifi
polypeptid
describ
paramyxovirus
protein
abund
polypeptid
infect
cell
polypeptid
correspond
nucleocapsidassoci
polypeptid
p
membran
protein
also
present
polypeptid
mw
found
infect
cell
precipit
antimump
viru
antiserum
uniqu
limit
proteolysi
peptid
map
consist
nonstructur
ns
polypeptid
mump
common
diseas
childhood
although
attack
adult
life
frequent
measl
chickenpox
exampl
suggest
reduc
infect
mump
compar
latter
virus
viru
spread
aerosol
initi
infect
upper
respiratori
tract
incub
period
vari
day
commonli
day
experiment
infect
children
viru
excret
saliva
day
clinic
sign
parot
appear
day
onset
approxim
half
suscept
person
may
never
develop
clinic
sign
mump
infect
although
commonli
secret
viru
sourc
infect
other
clinic
diseas
often
begin
malais
fever
pain
near
angl
jaw
typic
swell
face
develop
within
hour
often
distort
featur
consider
often
parotid
gland
affect
may
delay
onset
gland
patient
may
difficulti
open
mouth
often
dryness
throat
presum
reduc
saliva
flow
block
salivari
duct
temperatur
often
high
day
swell
last
day
subsid
quickli
notori
complic
mump
orchiti
develop
day
onset
parot
although
may
develop
absenc
preced
parot
first
indic
pain
testicl
rapidli
follow
swell
tender
pain
may
acut
often
accompani
sharp
gener
reaction
high
temperatur
head
ach
symptom
tend
subsid
day
estim
incid
orchiti
adult
mump
vari
averag
incid
usual
accept
clinician
degre
testicular
atrophi
common
may
occur
half
patient
seriou
complic
steril
estim
degre
infertil
may
expect
adult
patient
suffer
mump
orchiti
although
may
temporari
believ
fear
steril
follow
mump
greatli
exagger
import
complic
mump
children
mening
kilham
mclean
et
al
russel
donald
donohu
et
al
much
lesser
extent
enceph
howev
prognosi
asept
mening
extrem
good
report
long
term
sequela
mump
enceph
hand
sever
sometim
fatal
ill
tabl
essenti
lesion
demyelin
occur
foci
distribut
throughout
brain
spinal
cord
mump
viru
may
found
cerebrospin
fluid
brain
tissu
quit
often
first
indic
convuls
young
child
sudden
coma
older
child
adult
convalesc
period
mump
sharp
rise
temperatur
less
dramat
onset
may
includ
drowsi
chang
behaviour
extent
damag
cn
vari
consider
patient
may
recov
other
may
develop
paralysi
mortal
estim
around
overal
mortal
mump
death
per
report
case
rel
high
incid
subclin
mump
henl
et
al
patient
parot
may
infecti
even
clinic
sign
appear
method
prevent
base
isol
clinic
case
quarantin
contact
effect
therefor
work
pioneer
studi
ender
et
al
commenc
develop
inactiv
mump
vaccin
live
attenu
vaccin
buynak
hilleman
enni
hopp
henl
kliachko
maslennikova
stoke
et
al
uncertain
natur
antigen
composit
viru
poor
experi
inactiv
rsv
measl
vaccin
see
page
earli
experiment
inactiv
vaccin
although
use
quit
success
immun
young
armi
recruit
soon
superced
live
attenu
vaccin
neg
aspect
inactiv
mump
vaccin
poor
durat
immun
live
attenu
mump
vaccin
licens
usa
develop
strain
mump
jeryl
lynn
mumpsvox
initi
isol
fertil
hen
egg
sever
passag
adapt
chick
embryo
cell
cultur
earlier
attenu
virus
passag
egg
alon
prove
either
underaltenu
caus
mump
recipi
overattenu
provok
antibodi
recipi
origin
mump
vaccin
use
monoval
form
recent
also
use
usa
children
particularli
combin
vaccin
live
measl
rubella
virus
schwarz
et
al
schell
et
al
buynak
el
al
clinic
trial
year
establish
protect
efficaci
rang
mmwr
nov
good
correl
induct
viru
neutral
antibodi
clinic
protect
vaccin
prove
safe
usag
mumpslik
syndrom
could
attribut
vaccin
viru
control
clinic
trial
patient
includ
sever
hundr
potenti
suscept
adult
similar
vaccin
also
use
armi
recruit
pentinnen
et
al
sinc
licens
vaccin
decemb
usa
million
vaccin
dose
use
mump
vaccin
develop
sinc
particularli
japan
isomura
et
al
hosai
et
al
yamanishi
et
al
sinc
introduct
vaccin
progress
declin
number
report
case
mump
usa
thu
decreas
averag
annual
total
year
note
incid
mump
usa
reach
time
low
case
report
show
declin
case
import
immun
induc
mump
vaccin
last
adulthood
featur
vaccin
clearli
establish
earli
studi
longev
immun
admittedli
small
number
patient
weibel
et
al
weibel
et
al
report
substanti
declin
neutral
antibodi
titr
nearli
year
initi
level
neutral
antibodi
reach
vaccin
less
follow
natur
infect
even
serum
antibodi
titr
associ
solid
immun
infect
wild
viru
earli
exampl
attenu
mump
vaccin
one
still
use
today
alon
form
tripl
vaccin
jeryl
lynn
strain
name
child
viru
origin
isol
viru
attenu
empir
sequenti
passag
embryon
hen
egg
chick
embryo
cell
cultur
first
vaccin
prepar
use
viru
grown
latter
cell
hilleman
et
al
larg
field
trial
vaccin
given
subcutan
inject
studi
involv
total
children
children
assign
famili
classroom
group
classroomfamili
group
one
sibl
famili
also
enter
classroom
includ
studi
children
classroom
select
randomli
receiv
vaccin
serv
unvaccin
sentinel
enabl
studi
made
unwant
spread
vaccin
viru
children
receiv
vaccin
act
control
age
rang
eleven
month
eleven
year
clinic
reaction
record
day
vaccin
children
initi
seroneg
develop
antibodi
vaccin
seroconvers
tabl
none
contact
control
acquir
mump
surprisingli
recipi
vaccin
alreadi
mump
antibodi
often
display
increas
antibodi
titr
follow
vaccin
signific
clinic
reaction
follow
vaccin
occurr
natur
mump
commun
two
year
follow
immun
allow
assess
protect
efficaci
vaccin
tabl
among
famili
attack
rate
vaccine
control
protect
efficaci
final
freezedri
vaccin
could
produc
batch
consist
qualiti
stabl
storag
also
stabl
rehydr
similar
vaccin
use
wide
usa
combin
tripl
vaccin
live
rubella
measl
viru
long
term
followup
studi
indic
persist
antibodi
quit
extend
period
time
weibel
et
al
weibel
et
al
trial
new
mump
vaccin
report
recent
ehrengut
et
al
use
illustr
gener
featur
type
vaccin
see
also
isomura
et
al
rossier
et
al
urab
strain
deriv
mump
viru
isol
primari
human
embryon
kidney
cell
child
name
urab
typic
clinic
sign
symptom
mump
wild
viru
attenu
serial
passag
sever
substrat
takahashi
osaka
univers
japan
isol
passag
human
embryo
kidney
cell
hek
primari
green
monkey
kidney
cell
six
time
amniot
membran
specificpathogenfre
spf
hen
egg
twice
spf
quail
embryon
fibroblast
clone
passag
four
time
egg
stage
suppli
vaccin
manufactur
passag
five
time
chorioallanto
membran
spf
embryon
hen
egg
produc
seed
viru
vaccin
product
chick
embryo
fibroblast
none
subject
given
vaccin
two
clinic
trial
local
reaction
tabl
sero
convers
note
person
four
separ
group
twentyseven
subject
retest
antibodi
nearli
year
later
still
ehi
antibodi
although
level
drop
somewhat
thu
urab
mump
vaccin
strain
common
strain
use
wide
eg
jeryl
lynn
rel
well
toler
immunogen
although
complet
free
side
reaction
suggest
suscept
children
adolesc
adult
vaccin
mump
unless
vaccin
contraind
mump
vaccin
particular
valu
children
approach
puberti
adolesc
adult
especi
male
mump
childhood
live
mump
vaccin
recommend
children
age
month
although
recommend
younger
infant
persist
matern
antibodi
would
interfer
viru
take
contraind
includ
pregnanc
sinc
although
good
evid
mump
caus
congenit
abnorm
human
nevertheless
wild
viru
infect
foetu
placenta
mump
vaccin
viru
also
isol
placenta
although
foetu
sinc
viru
grown
chick
embryo
cell
cultur
person
allerg
egg
protein
vaccin
extrem
caution
person
immun
defici
diseas
suppress
immun
respons
occur
leukaemia
lymphoma
gener
malign
therapi
corticosteroid
alkyl
drug
radiat
vaccin
replic
mump
vaccin
viru
may
potenti
patient
immun
defici
diseas
principl
strategi
remov
burden
mump
diseas
usa
achiev
maintain
high
immun
level
cdc
constantli
encourag
privat
physician
public
health
clinic
carri
routin
vaccin
part
health
care
programm
exampl
achiev
state
massachusett
initi
mump
control
programm
offer
vaccin
year
old
begin
year
old
addit
save
achiev
cost
vaccin
programm
compar
cost
avoid
medic
care
seem
like
futur
mump
vaccin
direct
emphasi
put
rubella
measl
vaccin
combin
viru
vaccin
usa
least
proven
efficaci
easi
appli
without
seriou
side
effect
tabl
electron
microscopi
show
viru
nm
diamet
envelop
contain
surfac
project
fig
bloth
et
attempt
identifi
character
protein
rsv
hamper
sever
factor
loss
infect
purif
procedur
fact
sucros
bandpurifi
materi
nonvir
make
studi
purifi
viral
protein
difficult
ferni
gerin
may
account
discrep
among
tabl
fig
identifi
polyacrylamid
gel
electrophoresi
radiolabel
rsv
protein
gerin
bernstein
hruska
glycoprotein
glycoprotein
identifi
suggest
surfac
glycoprotein
base
upon
remov
trypsin
deterg
treatment
purifi
rsv
recent
glycoprotein
shown
connect
protein
disulfid
bond
form
protein
function
design
glycoprotein
made
k
protein
consid
nucleocapsid
n
protein
protein
consid
matrix
protein
peebl
levin
although
relat
paramyxovirus
rsv
possess
similar
biochem
marker
haemagglutinin
neuraminidas
activ
like
paramyxovirus
howev
rsv
promot
cellcel
fusion
account
characterist
giant
cell
syncytia
format
seen
viru
grown
permiss
cell
line
abil
form
syncytia
permit
spread
viru
fusion
infect
cell
adjac
noninfect
cell
presum
surfac
protein
virion
respons
fusion
process
demonstr
paramyxovirus
attempt
defin
socal
fusion
protein
rsv
walsh
hruska
produc
six
monoclon
antibodi
direct
respiratori
syncyti
viru
protein
character
immunoprecipit
indirect
immunofluoresc
one
direct
nucleocapsid
protein
n
p
two
direct
k
protein
two
direct
envelop
protein
tabl
indirect
immunofluoresc
stain
pattern
infect
cell
defin
g
p
vp
viral
protein
express
cell
surfac
wherea
np
protein
detect
intracytoplasm
inclus
one
antigp
antibodi
neutral
viru
presenc
peepl
levin
veba
cash
et
al
belsh
et
al
complement
inhibit
cellcel
fusion
antivp
antibodi
neutral
viru
without
complement
inhibit
cellcel
fusion
previous
infect
cell
thu
identifi
vp
fusion
protein
base
molecular
weight
surfac
locat
g
p
rsv
ferni
gerin
suggest
may
analog
haemagglutinin
paramyxovirus
function
viral
glycoprotein
respons
adsorpt
viru
cell
although
g
p
rsv
possess
haemagglutin
neuraminidas
activ
reason
suspect
also
might
function
cell
attach
inabl
neutral
rsv
two
antigp
monoclon
antibodi
negat
possibl
walsh
hruska
monoclon
antibodi
may
direct
toward
epitop
g
p
distinct
one
respons
virushost
cell
adsorpt
one
antigp
antibodi
capabl
neutral
viru
presenc
complement
suggest
neutral
mediat
viral
membran
lysi
antibodi
g
p
might
import
immun
infect
although
abl
neutral
rsv
presenc
complement
antigp
antibodi
unabl
prevent
spread
infect
cellcel
fusion
fusion
protein
may
involv
cell
penetr
step
envelop
virus
fuse
viral
envelop
host
cell
membran
result
deliveri
ribonucleoprotein
cell
cytoplasm
neutral
rsv
antivp
antibodi
might
mediat
inhibit
viruscel
fusion
antivp
monoclon
antibodi
describ
cote
et
al
abl
neutral
viru
inhibit
cellcel
fusion
suggest
either
fusion
protein
facilit
cell
adsorpt
neutral
viru
occur
mechan
inhibit
cell
attach
also
possibl
viruscel
fusion
cellcel
fusion
may
mediat
differ
region
fusion
protein
reinfect
rsv
presenc
circul
neutral
antibodi
common
infant
adult
hall
dougla
howev
protein
specif
neutral
antibodi
fulli
explor
cellcel
spread
rsv
neutral
antibodi
g
p
may
effect
prevent
infect
neutral
antibodi
direct
fusion
protein
also
limit
cellcel
spread
viru
cours
studi
particular
relev
regard
new
rsv
vaccin
particularli
vaccin
contain
protein
clone
gene
analysi
rs
virion
rna
viralspecif
messeng
mrna
synthes
infect
cell
initi
complet
seven
genet
complement
group
exist
firm
biochem
data
describ
number
gene
viral
genom
number
identif
gene
product
specifi
huang
wentz
present
data
suggest
rs
viru
negativestrand
rna
viru
one
characterist
neg
strand
viru
virion
contain
rna
depend
rna
polymeras
capabl
synthes
messeng
rna
presenc
inhibitor
protein
synthesi
wertz
establish
polypeptid
code
assign
six
rsv
mrna
translat
vitro
rna
band
complex
separ
least
two
compon
code
three
polypeptid
code
polypeptid
polypeptid
polypeptid
polypeptid
may
posttransl
modifi
protein
viru
import
caus
sever
respiratori
infect
young
infant
age
month
parrott
et
al
glezen
denni
holzel
et
al
gardner
report
mrc
loda
et
al
mcdonald
et
al
kim
et
al
may
also
infect
caus
exacerb
bronchiti
adult
close
correl
recoveri
rsv
cot
death
viru
ubiquit
temper
tropic
climat
may
caus
epidem
bronchiol
infant
sever
week
winter
infant
tend
shed
viru
week
may
import
focu
infect
even
leav
hospit
rsv
caus
mild
upper
respiratori
tract
infect
sever
attack
acut
bronchiol
often
attack
commenc
like
common
cold
within
hour
child
may
acut
ill
dyspnoea
distress
cyanos
infant
clinic
pictur
may
resembl
pneumonia
patholog
necrot
bronchiol
partial
block
bronchiol
lead
collaps
peribronchi
infiltr
may
spread
lung
give
widespread
interstiti
pneumonia
adult
detect
level
neutral
antibodi
rsv
actual
titr
antibodi
may
direct
relationship
abil
resist
infect
review
jackson
muldoon
sever
infect
rsv
period
year
rather
resist
infect
appear
correl
close
level
nasal
iga
antibodi
repeat
natur
infect
result
cumul
acquisit
resist
ill
soon
isol
rsv
delin
clinic
effect
young
children
chanock
et
realiz
protect
diseas
would
difficult
achiev
immun
moder
level
serum
neutral
antibodi
previou
natur
infect
protect
fulli
rsv
caus
low
respiratori
tract
ill
kapikian
et
al
howev
recent
data
summar
indic
natur
infect
induc
state
partial
immun
reinfect
detect
least
one
year
also
rsvcaus
bronchiol
pneumonia
occur
often
first
four
month
life
matern
transmit
antibodi
high
level
nevertheless
follow
preliminari
studi
formalin
inactiv
rsv
vaccin
adult
vaccin
use
immun
children
local
author
home
vaccin
util
bernett
strain
rsv
isol
origin
hek
human
embryo
kidney
cell
passag
time
hek
cell
time
vervet
mk
cell
k
cell
harvest
clarifi
filtrat
inactiv
formalin
safeti
test
anim
tissu
cultur
vaccin
control
group
compar
age
sex
race
signific
side
effect
follow
immun
vaccin
immunogen
children
lack
cf
antibodi
subsequ
develop
antibodi
inject
children
test
rel
high
level
neutral
antibodi
also
develop
approxim
month
later
sharp
outbreak
rsv
occur
home
viru
recov
x
resid
serolog
evid
infect
detect
seroneg
resid
vaccin
fail
induc
protect
induc
exagger
alter
clinic
respons
rsv
younger
vaccine
nine
vaccin
children
month
age
develop
pneumonia
compar
nonvaccin
children
tabl
five
vaccin
children
develop
pneumonia
seriou
enough
requir
hospit
wherea
none
nonvaccin
children
hospit
paradox
effect
vaccin
observ
arthur
cottag
hous
older
children
month
age
lack
protect
ill
observ
kapikian
et
al
consid
failur
produc
protect
older
children
may
due
poor
induct
local
produc
iga
antibodi
observ
previous
parainfluenza
type
viru
infect
wherea
enhanc
clinic
effect
note
younger
infect
children
may
result
interact
serum
antibodi
rsv
antigen
lung
children
lack
respiratori
tract
iga
antibodi
author
also
conclud
administr
gamma
globulin
infant
approach
caution
period
rsv
preval
essenti
ident
result
paradox
respons
rsv
immun
also
report
kim
et
al
respons
three
inject
alum
precipit
x
concentr
formalin
inactiv
rsv
vaccin
infant
vaccine
display
greater
rise
serum
neutral
antibodi
display
greater
rise
serum
cf
antibodi
rsv
becam
preval
commun
rate
rsv
infect
infant
receiv
vaccin
differ
control
infant
receiv
parainfluenza
vaccin
howev
high
proport
rsv
vaccine
requir
hospit
time
rsv
infect
wherea
infect
among
parainfluenza
vaccine
control
group
result
admiss
hospit
see
also
tabl
ill
among
rsv
vaccine
underw
natur
infect
includ
pneumonia
bronchiol
bronchiti
pneumonia
major
rhiniti
pharyng
bronchiti
thu
infant
receiv
vaccin
protect
natur
infect
also
becam
natur
infect
ill
sever
seen
cohort
receiv
similar
parainfluenza
type
vaccin
find
similarli
kapikian
et
al
indic
vaccineinduc
rsv
serum
antibodi
alon
protect
ill
suggest
serum
antibodi
particularli
certain
viral
protein
without
local
respiratori
antibodi
might
actual
play
part
product
diseas
highest
incid
seriou
rsv
ill
occur
natur
six
month
age
matern
deriv
serum
antibodi
present
find
togeth
kapikian
et
al
suggest
rsv
ill
infant
least
part
immunolog
phenomenon
wherein
viru
serum
antibodi
interact
produc
sever
ill
sinc
antirsv
serum
igg
antibodi
matern
origin
antibodi
induc
inactiv
rsv
vaccin
fail
produc
protect
natur
diseas
kapikian
et
al
effort
commenc
make
cold
adapt
ca
fs
viru
could
use
candid
strain
live
vaccin
gharpur
et
al
belsh
et
vaccin
would
presum
induc
local
iga
antibodi
respiratori
tract
close
mimic
natur
infect
rsv
initi
experi
ca
viru
kim
et
al
adapt
fail
produc
complet
attenu
viru
exampl
child
given
viru
develop
mild
lower
respiratori
tract
diseas
group
use
standard
mutagenesi
techniqu
wright
et
al
produc
ts
mutant
design
mutant
propag
primari
bovin
embryo
kidney
cell
infect
cell
vivo
hamster
model
ts
mutant
infect
upper
respiratori
tract
moreov
laboratori
evid
phenotyp
revers
import
problem
ts
virus
initi
experi
adult
infect
intranas
indic
diseas
produc
vaccine
resist
subsequ
challeng
virul
wild
type
viru
wright
et
al
next
step
infect
infant
children
viru
use
coars
spray
mutant
produc
infect
infant
shown
recoveri
viru
tabl
increas
antibodi
titr
tabl
children
excret
vaccin
viru
mean
day
kim
et
al
anoth
candid
live
attenu
rsv
vaccin
strain
found
un
suitabl
work
overattenu
review
test
adult
volunt
slight
evid
infect
none
volunt
shed
viru
antibodi
respons
similarli
two
seven
seroneg
children
infect
anoth
approach
live
viru
vaccin
administ
parenter
test
vaccin
prepar
passag
clinic
isol
rsv
cell
random
doubleblind
placebocontrol
trial
encompass
children
receiv
vaccin
receiv
placebo
children
low
level
preexist
neutral
antibodi
respond
vaccin
wherea
seroneg
children
produc
antibodi
titr
lower
observ
children
natur
infect
rsv
infect
occur
variou
group
similar
rate
children
preepidemicpostepidem
serum
pair
avail
placebo
recipi
vaccin
recipi
serolog
evid
rsv
infect
placebo
recipi
vaccine
develop
rsv
ill
confirm
viral
isol
thu
parenter
administ
live
rsv
vaccin
protect
subsequ
rsv
infect
ill
simpli
repeat
neg
result
earlier
trial
kill
vaccin
document
among
studi
children
ill
requir
hospit
respiratori
tract
diseas
studi
five
ill
caus
rsv
infect
determin
isol
viru
fourfold
increas
antibodi
titr
three
rsv
ill
vaccin
group
two
placebo
group
fortun
none
ill
particularli
sever
none
lifethreaten
n
untoward
clinic
reaction
note
infant
tabl
although
infant
mild
nonfebril
rhiniti
note
howev
two
worri
featur
vaccin
strain
spread
nonvaccine
laboratori
evid
revers
wildtyp
phenotyp
thu
total
virus
recov
vaccine
show
evid
genet
alter
ts
phenotyp
virus
complet
lost
ts
properti
although
revert
repres
less
viru
produc
respiratori
tract
time
peak
viru
replic
nevertheless
made
vaccin
unsuit
widespread
use
experi
altern
ts
mutant
still
progress
richardson
et
al
allud
poor
growth
rsv
tissu
cultur
system
hamper
biochem
work
viru
polypeptid
rna
composit
recent
describ
wertz
pringl
et
al
n
satisfactori
vaccin
develop
use
convent
biolog
method
hall
employ
success
mani
virus
therefor
remain
possibl
appli
recombin
dna
techniqu
isol
gene
product
also
analyz
structur
natur
express
rsv
genom
venkatesan
et
al
complementari
cdna
clone
construct
contain
rsv
n
p
ns
gene
sequenc
author
assum
gene
order
rsv
similar
paramyxovirus
name
nfo
p
h
n
l
case
venkatesan
et
al
clone
contain
sequenc
adjac
foand
hn
equival
possibl
obtain
cdna
code
fo
hn
equival
rsv
cdna
clone
could
also
transfer
eukaryot
express
vector
fusion
major
surfac
glycoprotein
antigen
would
requir
new
inactiv
vaccin
dubovi
et
al
dubovi
et
al
describ
inhibit
rsv
induc
cell
fusion
cell
aromat
diamidin
bi
methan
babim
activ
vitro
pm
effect
rs
viru
specif
extend
parainfluenza
type
sv
strain
exampl
compound
appear
retard
viru
penetr
reduc
yield
viru
multipl
growth
cycl
condit
tabl
postul
fusion
within
inhibit
compound
known
potent
revers
inhibitor
trypsin
compound
inhibit
plaqu
format
long
strain
rsv
concentr
pgml
cell
tabl
similarli
wild
strain
viru
inhibit
vitro
although
rather
less
suscept
laboratori
virus
hruska
et
al
reduct
releas
rsv
detect
viru
induc
cytopath
effect
reduc
ribavirin
compound
therefor
appear
inhibit
rsv
extent
influenza
b
virus
see
page
experi
hruska
et
al
demonstr
mild
vivo
inhibit
rsv
replic
nasal
turbin
lung
tissu
infect
cotton
rat
antivir
effect
detect
ribavirin
administ
aerosol
intranas
also
intraperiton
tabl
hall
et
al
infect
young
adult
intranas
rsv
log
treat
ribavirin
aerosol
commenc
day
hour
per
day
day
viru
shed
first
clinic
sign
normal
commenc
day
aerosol
given
period
h
use
face
mask
estim
h
treatment
would
provid
deposit
dose
mg
ribavirin
per
patient
averag
onset
viru
shed
placebotr
group
day
significantli
differ
ribavirintr
group
day
x
compar
ribavirintr
subject
x
tcid
differ
howev
statist
signific
first
three
day
shed
day
studi
proport
subject
shed
viru
significantli
differ
two
group
latter
part
studi
day
howev
hour
ribavirin
treatment
proport
infect
subject
still
shed
viru
significantli
less
ribavirintr
group
p
twelv
infect
subject
manifest
sign
symptom
upper
respiratori
tract
ill
one
subject
ribavirintr
group
remain
asymptomat
frequenc
occurr
minor
upper
respiratori
tract
symptom
differ
significantli
two
group
frequenc
howev
major
complaint
system
symptom
cough
fever
occur
significantli
often
placebotr
group
tabl
nine
record
oral
temperatur
placebotr
subject
greater
c
compar
one
record
temperatur
ribavirintr
group
p
similarli
averag
symptom
score
minor
symptom
significantli
differ
two
group
score
obtain
system
symptom
fever
significantli
greater
placebotr
group
tabl
note
infect
mild
even
ribavirin
amelior
system
symptom
cough
temperatur
howev
toxic
sign
drug
note
suggest
treatment
could
extend
hall
et
al
also
describ
treatment
infant
hospit
rsv
infect
aerosol
ribavirin
compound
administ
continu
except
period
hour
morn
minimum
day
give
adult
approxim
mg
per
kg
drug
per
hour
thirtythre
infant
studi
rsv
pneumonia
admiss
hospit
sever
ill
placebo
treat
group
day
therapi
differ
clinic
improv
group
favour
ribavirin
detect
chang
degre
improv
lower
respiratori
tract
sign
except
wheez
significantli
greater
drug
treat
group
wherea
chang
temperatur
upper
respiratori
tract
sign
end
treatment
quantiti
viru
nasal
wash
ribavirin
group
significantli
less
tabl
moreov
averag
number
day
rsv
shed
start
therapi
day
placebo
group
day
ribavirin
group
final
toxic
side
effect
aerosol
therapi
detect
infant
sinc
ribavirin
therapi
administ
aerosol
long
period
appropri
time
hospit
infant
number
infant
requir
hospit
rsv
infect
nevertheless
appreci
longterm
studi
washington
dc
infect
viru
account
hospit
case
acut
respiratorytract
diseas
one
everi
primari
rsv
infect
result
hospit
admiss
parrott
et
al
uk
rate
hospit
rsv
infect
high
everi
infant
first
year
life
ribavirin
therapi
may
particularli
benefici
children
risk
sever
often
fatal
rsv
infect
infant
congenit
heart
diseas
macdonald
et
al
measl
anglosaxon
word
middl
english
masel
true
form
diseas
still
regard
earlier
time
almost
normal
incid
anglosaxon
childhood
certainli
countri
exampl
us
may
soon
rid
indigen
measl
may
therefor
becom
island
countri
vigor
immun
polici
ijssr
sweden
ddr
measl
also
implic
least
one
neurolog
diseas
result
persist
viral
infect
name
subacut
scleros
panenceph
sspe
hall
ter
meulen
modlin
et
al
also
fatal
encephalopathi
immunosuppress
oldingstenkvist
et
al
mw
x
measl
viru
genom
rna
obtain
intermedi
valu
neg
strand
virus
x
loh
vsv
x
rsv
agreement
estim
number
viru
code
protein
name
vsv
measl
rsv
studi
viru
protein
carri
last
year
paramyxovirus
formid
difficulti
overcom
viru
purif
appear
viru
typic
paramyxoviru
fig
virion
appear
six
protein
similar
typic
paramyxovirus
name
l
h
p
n
f
precis
role
mani
protein
still
specul
even
question
whether
h
f
protein
present
singl
complex
spike
viru
unknown
nucleocapsid
n
protein
directli
associ
rna
genom
major
protein
paramyxovirus
virion
viru
infect
cell
electrophoret
mobil
n
vari
among
measl
viru
strain
rima
chang
could
caus
phosphoryl
protein
n
protein
major
crossreact
protein
morbillivirus
although
monoclon
antibodi
may
use
distinguish
differ
member
group
birrer
et
al
b
p
protein
formerli
call
second
largest
structur
protein
design
p
associ
rna
polymeras
molecular
weight
phosphoryl
may
contribut
observ
electrophoret
variat
measl
viru
strain
p
protein
suscept
proteolysi
exampl
measl
viru
infect
cell
protein
deriv
p
describ
rima
et
al
l
protein
largest
protein
glycosyl
molecular
weight
present
purifi
viru
vainionpaa
infect
cell
l
protein
appear
phosphoryl
identifi
viru
specif
use
monoclon
antibodi
giraudon
wild
l
protein
minor
compon
virion
ha
protein
h
g
protein
major
glycoprotein
detect
virion
molecular
weight
infect
cell
virion
h
protein
present
dimer
variat
electrophoret
mobil
h
protein
observ
among
strain
measl
viru
monospecif
antisera
h
protein
measl
viru
neutral
hi
activ
monoclon
antibodi
haemolysisinhibit
antibodi
antigen
variat
among
h
protein
measl
virus
also
detect
monoclon
antibodi
birrer
et
al
fusion
glycoprotein
f
convert
biolog
activ
form
f
proteolysi
result
polypeptid
held
togeth
disulphid
bond
morbillivirus
fi
glycosyl
portion
f
protein
glycosyl
detect
glycopolypeptid
proteolyt
activ
f
protein
appear
depend
cell
line
viru
replic
membran
matrix
protein
smallest
abund
protein
viru
molecular
weight
k
mountcastl
choppin
protein
detect
measl
viru
infect
cell
certain
salt
condit
associ
purifi
nucleocapsid
complex
protein
glycosyl
purifi
extract
kci
protein
measl
sspe
virus
distinguish
fingerprint
techniqu
hall
et
protein
thought
role
viru
assembl
bud
may
function
viru
persist
sinc
antigen
composit
electrophoret
characterist
differ
persist
viru
compar
acut
infect
viru
ter
meulen
carter
sera
sspe
patient
reduc
antibodi
frequenc
titr
measl
viru
protein
hall
et
al
macham
et
number
sspe
strain
describ
produc
reduc
amount
infect
cell
macham
et
al
sspe
strain
also
produc
reduc
amount
h
f
protein
possibl
certain
sspe
viru
protein
may
rapidli
degrad
altern
may
defect
transcript
translat
variou
rna
precis
definit
nonstructur
protein
must
await
studi
candid
ns
protein
detect
measl
infect
cell
molecular
weight
review
rima
measl
viru
enter
bodi
infect
via
droplet
spread
perhap
also
via
conjunctiva
incub
period
day
viru
spread
nearest
lymph
node
replic
soon
detect
bloodstream
spleen
liver
bone
marrow
organ
fenner
certain
symptom
viru
induc
lesion
rash
fig
probabl
due
inflammatori
reaction
releas
abnorm
cell
product
viru
infect
cell
giant
cell
contain
nuclei
describ
pharynx
tonsil
skin
respiratori
epithelium
lymph
node
peyer
patch
brain
viru
widespread
skin
disappear
quickli
time
skin
react
rash
appar
viru
content
intern
organ
drop
within
day
littl
viru
excret
infecti
stage
diseas
sever
day
rash
littl
doubt
measl
one
ubiquit
human
virus
world
wide
distribut
caus
diseas
climat
environ
assaad
hethcot
countri
high
standard
live
epidem
occur
cycl
everi
year
attack
predominantli
yearold
rel
mild
way
tabl
third
world
countri
hand
measl
high
incid
year
old
sever
diseas
unusu
clinic
featur
blind
high
fatal
rate
tabl
morley
smith
foster
wakeham
state
nutrit
may
affect
viru
epidemiolog
malnutrit
may
reduc
immun
respons
chen
et
al
dossetor
whittl
measl
accentu
effect
malnutrit
diarrhoea
exampl
may
persist
measl
lead
protein
loss
death
rate
record
afghanistan
exampl
children
age
year
respect
certain
clinic
featur
measl
third
world
countri
today
resembl
descript
measl
europ
year
ago
heymann
et
al
complic
measl
children
europ
croup
otiti
media
eye
complic
central
nervou
system
chang
croup
often
complic
prodrom
phase
nearli
everi
child
sharp
attack
measl
symptom
bronchiti
xray
sign
pneumon
viru
inva
sion
respiratori
tract
miller
underdevelop
countri
bacteri
pneumonia
common
often
fatal
complic
measl
includ
pneumococci
haemolyt
streptococci
h
influenza
viru
pneumonia
caus
measl
report
children
north
africa
fatal
rate
may
approach
otiti
media
use
common
complic
measl
nowaday
much
reduc
possibl
slow
chang
diseas
rather
use
antibiot
convuls
commonest
rash
appear
often
classic
febril
convuls
incid
measl
enceph
approxim
case
drowsi
irrit
common
measl
actual
incid
may
much
higher
mortal
patient
coma
around
subacut
scleros
panenceph
sspe
occur
rate
approxim
per
measl
case
sinc
patient
infect
prodrom
period
isol
rash
serv
littl
purpos
must
orient
particularli
toward
vaccin
specif
antivir
prevent
measl
epidem
diseas
immunoglobulin
given
intramuscularli
mg
infant
mg
year
old
contact
within
day
exposur
measl
either
prevent
modifi
diseas
immunoglobulin
prophylaxi
consid
valuabl
measur
person
special
risk
vaccin
cours
could
consid
use
present
wider
scale
sinc
first
produc
live
attenu
measl
vaccin
eg
endersedmonston
isol
boy
name
passag
time
kidney
cell
time
primari
amnion
cell
time
chick
embryo
produc
unaccept
side
reaction
children
ender
et
al
initi
recommend
either
vaccin
given
gamma
globulin
kill
measl
vaccin
administ
first
follow
sever
month
booster
live
attenu
viru
mrc
report
practic
discontinu
develop
suitabl
attenu
virus
eg
schwartz
strain
produc
addit
passag
edmonston
viru
chick
embryo
fibroblast
cell
krugman
also
untoward
side
reaction
note
children
given
combin
emphas
caution
vaccin
trial
proceed
particularli
virus
viru
structur
unknown
regard
mcnairscott
bonanno
describ
febril
f
ill
patient
given
inactiv
measl
vaccin
cours
follow
challeng
live
measl
viru
red
swell
site
inject
live
viru
vaccin
note
blister
develop
cyst
patient
tabl
clinic
appear
arthu
type
immunolog
reaction
sensitis
person
moreov
norrbi
describ
occurr
averag
state
durat
therapi
day
patient
vesicular
petechi
rash
swollen
hand
feet
pneumonia
case
erythema
multiform
report
fulgin
et
al
describ
atyp
measl
ill
children
receiv
inactiv
measl
vaccin
year
earlier
tabl
ill
character
day
prodrom
fever
pain
follow
maculopapular
rash
petechi
vesicular
compon
peripher
oedema
pneumonia
occur
almost
children
children
hospit
judg
serious
ill
fact
rocki
mountain
spot
fever
misdiagnos
one
case
author
conclud
case
repres
fraction
total
commun
recommend
inactiv
measl
vaccin
discontinu
nowaday
live
attenu
measl
vaccin
mrc
report
miller
krugman
use
highli
effect
vaccin
tabl
vaccin
given
current
children
earlier
month
matern
antibodi
prefer
month
age
vaccin
administ
children
acut
leukaemia
immunosuppress
mitu
et
al
aicardi
et
al
detail
follow
studi
children
given
singl
dose
live
attenu
measl
vaccin
schwartz
strain
month
year
age
high
level
protect
note
mrc
report
tabl
moreov
immun
last
year
period
tabl
throughout
trial
measl
occur
vaccin
children
case
mild
unvaccin
children
tabl
exampl
sever
case
atyp
measl
note
usa
multipl
dose
inactiv
measl
vaccin
fulgin
et
al
note
persist
clinic
protect
also
confirm
serolog
investig
show
one
child
sampl
investig
tabl
detect
antibodi
year
common
reaction
associ
attenu
measl
vaccin
strain
use
norrbi
fever
rash
occur
recipi
gener
second
week
immun
febril
convuls
rare
recent
publish
studi
uk
involv
children
vaccin
schwartz
vaccin
viru
mild
symptom
moder
symptom
sever
symptom
two
week
vaccin
children
seen
doctor
possibl
seriou
side
effect
admit
hospi
tal
nine
convuls
latter
group
febril
incid
febril
convuls
two
week
period
three
time
expect
children
age
month
rememb
convuls
due
natur
measl
age
time
frequent
note
vaccin
miller
furthermor
intens
surveil
follow
use
x
dose
live
measl
vaccin
usa
establish
enceph
incid
low
per
million
dose
vacciq
compar
incid
per
due
natur
measl
compar
situat
centr
diseas
control
usa
establish
system
monitor
advers
effect
measl
vaccin
ill
occur
within
week
vaccin
immun
project
report
tabl
unfortun
report
privat
sector
usa
much
less
reliabl
henc
complet
assess
risk
possibl
howev
report
case
neurolog
event
exclud
case
febril
seizur
within
day
immun
live
measl
viru
one
patient
die
three
case
diagnosi
enceph
encephalopathi
includ
rey
syndrom
person
less
year
age
approxim
case
per
vaccin
cours
possibl
case
technic
point
view
measl
polio
could
follow
smallpox
erad
worldwid
mass
immun
campaign
note
seriou
morbid
also
mortal
caus
measl
inde
estim
death
annual
underdevelop
countri
caus
measl
accept
reason
accur
hinman
compar
contrast
measl
smallpox
regard
sever
factor
relev
worldwid
erad
tabl
note
measl
share
six
favour
characterist
smallpox
three
import
differ
factor
smallpox
lower
infect
measl
spread
rapidli
suscept
popul
therefor
smallpox
sometim
erad
area
overal
immun
rate
low
fact
contain
polici
use
wherebi
smallpox
case
discov
contact
immedi
area
vaccin
see
chapter
contrast
know
measl
may
still
transmit
commun
immun
level
hand
clear
measl
persisr
indefinit
condit
strong
immun
pressur
crucial
remain
factor
could
strongli
influenc
campaign
amount
intern
support
global
immun
campaign
measl
answer
may
ambigu
help
countri
immun
rate
low
tabl
satisfactori
result
usa
ussr
ddr
howev
would
like
stimul
intern
interest
alreadi
anoth
countri
canada
consid
nation
programm
measl
erad
worthwhil
analyz
experi
one
countri
usa
hope
repeat
note
vaccin
prepar
chick
embryo
cell
cultur
except
yugoslavian
vaccin
prepar
human
diploid
cell
iranian
aikc
strain
prepar
r
c
human
diploid
cell
ussr
vaccin
prepar
quail
embryo
cell
mani
viru
strain
use
although
deriv
edmonston
b
strain
viru
viru
often
adminst
im
earlier
experi
ussr
use
intranas
administr
reevalu
sabin
et
al
good
preliminari
result
see
also
leon
de
coto
rissi
assaad
rey
et
al
countri
shall
also
briefli
review
current
progress
vaccin
campaign
ijssr
sweden
immun
achiev
ddr
alaska
usa
sinc
recent
data
avail
latter
countri
use
exampl
goal
establish
elimin
indigen
measl
usa
octob
major
element
strategi
high
immun
level
effect
surveil
aggress
outbreak
control
obvious
precis
goal
yet
achiev
may
well
reach
year
sinc
live
measl
vaccin
licens
approxim
million
dose
use
usa
includ
million
dose
edmcnston
b
vaccin
million
dose
attenu
viru
strain
sinc
earli
seventi
combin
measl
mump
rubella
vaccin
use
exampl
measl
vaccin
use
combin
formul
similarli
ussr
million
dose
measl
vaccin
use
gener
set
background
measl
erad
campaign
usa
involv
childhood
immun
initi
two
goal
ensur
least
children
usa
receiv
vaccin
prevent
diseas
childhood
measl
rubella
mump
polio
diphtheria
tetanu
pertussi
sinc
even
estim
mani
million
children
year
lack
protect
agent
usa
develop
perman
system
maintain
level
protect
key
factor
campaign
identifi
unvaccin
school
children
medic
record
million
school
children
review
ensur
high
percentag
popul
would
continu
protect
immun
requir
enforc
strictli
condit
enter
attend
school
juli
state
usa
law
requir
children
proof
immun
enter
school
first
time
addit
state
requir
proof
student
level
kindergarten
high
school
vigor
enforc
school
immun
law
seem
singl
import
factor
immun
campaign
student
provid
documentari
evid
immun
measl
exclud
school
fact
experi
shown
success
school
year
children
respect
vaccin
measl
constant
pressur
exert
maintain
immun
programm
shown
introduct
rubella
vaccin
interest
divert
measl
case
increas
approxim
case
case
report
tabl
increas
public
support
figur
forc
case
howev
stress
univers
agreement
mean
behind
rise
fall
sabin
l
exampl
attribut
period
rise
fall
number
report
measl
case
buildup
suscept
person
rise
fall
vaccin
suggest
mass
vaccin
carri
short
time
transmiss
measl
would
broken
period
report
measl
death
declin
significantli
usa
around
less
present
similarli
number
report
case
measl
enceph
declin
around
around
present
sinc
sspe
consid
rare
complic
natur
measl
prime
import
monitor
case
might
caus
vaccin
viru
howev
sinc
mark
declin
report
sspe
case
usa
estim
risk
sspe
follow
wild
measl
much
higher
case
per
million
measl
case
risk
sspe
follow
measl
vaccin
viru
per
million
measl
vaccin
u
k
contrast
children
year
suffer
measl
die
immun
follow
administr
live
measl
vaccin
appear
long
last
case
year
fig
even
person
antibodi
longer
detect
may
still
immunolog
memori
may
immun
vaccin
failur
result
patient
serolog
convert
primari
failur
immun
subsequ
lost
follow
success
initi
seroconvers
secondari
failur
primari
failur
rate
usa
less
attribut
impot
vaccin
improp
storag
handl
interfer
vaccin
viru
replic
preexist
measl
antibodi
secondari
failur
follow
live
measl
vaccin
demonstr
conclus
measl
import
geograph
widespread
usa
rise
proport
import
case
occur
among
us
citizen
return
oversea
travel
case
measl
report
import
repres
total
measl
case
period
increas
proport
measl
case
young
adult
recent
year
tabl
result
initi
vaccin
programm
adult
includ
militari
camp
fortun
young
adult
appear
increas
risk
seriou
ill
measl
vaccin
viru
measl
incid
arm
forc
us
drop
sharpli
result
measl
immun
programm
initi
vaccin
certif
requir
attend
militari
school
daycar
centr
teacher
vaccin
proof
immun
epidemiologist
agre
complet
erad
indigen
measl
eventu
achiev
herd
immun
might
achiev
success
routin
give
second
dose
measl
vaccin
individu
particularli
citi
area
mani
immigr
although
current
nationwid
vaccin
rate
high
usa
envi
mani
countri
accru
social
medic
benefit
nevertheless
alway
level
estim
necessari
herd
immun
local
herd
immun
achiev
vaccin
programm
still
continu
indefinit
prevent
outbreak
import
case
mass
measl
vaccin
n
ussr
mass
vaccin
measl
viru
start
ussr
although
republ
start
earli
burgasov
et
al
attenu
measl
viru
use
campaign
peradz
smorodintsev
year
vaccin
high
morbid
due
measl
note
ussr
averag
incid
case
per
popul
scale
vaccin
increas
steadi
declin
morbid
follow
earli
measl
incid
drop
serolog
analysi
show
viru
induc
immun
persist
least
year
thu
children
sera
analyz
period
year
end
first
year
children
antibodi
subsequ
year
small
proport
children
appear
lost
antibodi
actual
antibodi
titr
remain
rel
constant
period
howev
point
note
although
antibodi
detect
blood
vaccin
children
nevertheless
resist
actual
infect
author
estim
year
vaccin
ussr
save
million
dollar
save
use
measl
gamma
globulin
alon
repaid
expens
connect
cost
vaccin
administr
gener
vaccin
combin
measl
mump
rubella
vaccin
introduc
sweden
see
christenson
et
al
new
immun
schedul
compris
two
vaccin
inject
given
month
year
age
respect
see
chapter
vaccin
month
abandon
risk
increas
number
peopl
remain
unprotect
among
left
unvaccin
fail
seroconvert
first
inocul
inde
occur
usa
see
aim
new
strategi
rapid
elimin
three
diseas
control
field
studi
carri
children
age
month
use
two
differ
batch
vaccin
seroconvers
seen
measl
fever
rash
side
effect
vaccin
record
five
day
vaccin
moder
fever
c
observ
children
high
fever
c
rash
even
high
fever
children
particularli
ill
fret
preliminari
result
obtain
follow
routin
vaccin
schoolchildren
age
indic
consider
lower
rate
fever
rash
postvaccin
period
occur
case
least
costli
way
deliv
viru
vaccin
patient
combin
recommend
mmwr
approach
success
must
interfer
virus
immun
viru
persist
extent
would
follow
administr
viru
alon
weibel
et
al
clinic
reaction
must
low
nonexist
combin
live
vaccin
develop
use
particularli
usa
ussr
use
extens
uk
rest
europ
present
buynak
et
al
stoke
et
al
schiff
sabin
weibel
et
al
serolog
convers
rate
four
differ
combin
viru
vaccin
moreov
quantiti
antibodi
induc
compar
virus
given
alon
viru
use
great
import
sinc
less
attenu
measl
vaccin
combin
mump
viru
lower
respons
mump
detect
perhap
unexpectedli
fever
note
side
reaction
caus
measl
compon
two
host
factor
seem
primari
import
explain
measl
sever
develop
countri
compar
diseas
unit
state
europ
first
children
experi
infect
younger
age
second
usual
poorli
nourish
walsh
note
tabl
peak
age
incid
diseas
urban
area
develop
countri
one
three
year
unit
kingdom
europ
five
year
older
unit
state
year
gener
infant
toddler
like
experi
complic
die
measl
older
children
deathtocas
ratio
infant
less
one
year
age
mani
time
greater
older
children
factor
lead
high
mortal
measl
develop
area
malnutrit
walsh
sever
malnourish
children
suffer
complic
like
die
betternourish
peer
nigerian
civil
war
observ
made
time
sever
famin
reveal
children
infect
measl
die
medic
centr
treatment
kwashiorkor
die
smith
foster
india
among
children
hospit
measl
poorli
nourish
one
complic
eg
pneumonia
otiti
stomat
diarrhoea
wellnourish
one
complic
chen
et
al
measl
malnourish
children
differ
markedli
diseas
usual
seen
unit
state
europ
rash
becom
dark
redpurpl
exfoli
extens
expos
larg
area
epitheli
surfac
bacteri
invas
sever
chang
occur
mouth
trachealbronchi
tree
intestin
extrem
sore
mouth
stomat
prevent
child
eat
drink
bronchopneumonia
persist
diarrhoea
proteinlos
enteropathi
ensu
axton
xerophthalmia
result
blind
occur
area
world
diet
defici
vitamin
area
half
incid
blind
may
attribut
measl
walsh
viral
excret
persist
much
longer
poorli
nourish
patient
day
rather
three
day
wellnourish
persist
viru
lymphocyt
intestin
cell
suggest
delay
product
lymphocyt
compet
destroy
cell
result
viru
multipli
longer
period
cell
infect
diseas
sever
addit
depress
cellular
immun
system
increas
patient
suscept
secondari
infect
dossetor
et
al
bronchopneumonia
diarrhoea
common
caus
death
measl
heat
labil
measl
vaccin
greatli
complic
effort
distribut
tropic
climat
freezedri
vaccin
held
minut
inject
unless
temperatur
rang
maintain
vaccin
rapidli
lose
potenc
howev
last
year
new
stabil
develop
retard
heat
inactiv
heymann
et
al
presenc
stabil
titr
attenu
viru
remain
adequ
median
tissu
cultureinfect
dose
per
dose
three
week
six
month
laboratori
mcaleer
et
al
field
trial
children
nine
month
age
older
seroconvert
receiv
vaccin
store
seven
eight
day
heymann
et
al
final
problem
provid
effect
immun
children
develop
countri
reach
brief
interv
loss
matern
antibodi
acquisit
natur
diseas
soon
matern
antibodi
wane
infant
begin
acquir
diseas
ideal
child
vaccin
soon
transplacent
immun
fade
soon
hisher
immun
system
adequ
respond
vaccin
six
month
age
least
children
matern
antibodi
infant
vaccin
viru
multipli
protect
achiev
immun
seroconvert
develop
protect
immun
howev
develop
countri
children
may
alreadi
measl
immun
delay
age
nine
month
walsh
medic
research
centr
nairobi
measl
vaccin
part
world
health
organ
expand
programm
immun
vaccin
diphtheria
pertussi
tetanu
poliomyel
infect
administ
simultan
measl
vaccin
reliabl
comprehens
deliveri
system
avail
prophylaxi
malaria
oral
rehydr
well
health
educ
measur
could
easili
combin
measl
immun
effort
walsh
present
rate
immun
children
measl
southeast
asia
low
children
immun
compar
europ
recent
observ
unit
republ
cameroon
support
recommend
one
dose
measl
vaccin
tropic
africa
month
minimum
age
measl
control
activ
capit
citi
began
mass
vaccin
campaign
held
everi
year
among
children
age
month
howev
despit
sampl
survey
show
children
citi
vaccin
case
measl
among
children
deduc
vaccin
given
ineffect
preexist
immun
mother
use
impot
vaccin
storag
problem
new
storag
facil
introduc
also
new
polici
vaccin
month
decreas
report
measl
attack
rate
among
children
month
age
report
heymann
et
al
earli
experi
ussr
terskikh
et
japan
okuno
et
al
indic
administr
aerosol
live
measl
vaccin
could
result
seroconvers
even
circumst
partial
immun
prevent
seroconvers
vaccin
inject
intramuscularli
sabin
et
al
adapt
simpl
aerosol
apparatu
would
suitabl
use
third
world
countri
larg
number
nonprofession
personnel
inhal
undilut
aerosol
measl
vaccin
immunogen
older
children
without
residu
matern
antibodi
human
diploid
cell
hdc
vaccin
contain
ikic
edmonstonzagreb
st
rain
human
albumin
use
prevaccin
residu
placentallytransmit
plaqueneutr
antibodi
prevent
immun
respons
subcutan
inject
measl
vaccin
prevent
immun
respons
inhal
aerosol
vaccin
immedi
clinic
reaction
children
inhal
aerosol
vaccin
n
signific
subsequ
reaction
among
children
success
immun
contact
infect
compar
favour
exampl
studi
nairobi
kenya
show
measl
vaccin
failur
infant
vaccin
subcutan
month
age
respect
mrc
studi
south
america
show
failur
seroconvers
infant
month
age
respect
subcutan
inject
measl
vaccin
sabin
studi
found
inhal
aerosol
hdc
vaccin
contain
ikic
edmonstonzagreb
plaquepurifi
strain
measl
viru
tkic
et
al
attenu
hdc
human
albumin
immun
infant
month
age
children
month
age
without
refer
amount
matern
antibodi
measur
vaccin
seroconvers
evid
six
week
vaccin
four
infant
month
age
residu
matern
antibodi
titr
seroconvers
becam
evid
blood
obtain
six
month
vaccin
howev
rather
worri
observ
anoth
measl
vaccin
cultiv
cef
cell
achiev
seroconvers
given
aerosol
even
although
contain
ten
time
viru
ad
protein
studi
requir
determin
whether
human
diploid
vaccin
intrins
immunogen
whether
human
albumin
stabil
viru
aerosol
infect
gener
state
practic
econom
success
tneasl
vaccin
tabl
reduc
need
effect
prophylact
agent
nevertheless
compound
cheapli
produc
could
use
third
world
countri
develop
countri
special
group
children
high
risk
immun
measl
viru
inhibit
vitro
nucleosid
analogu
ribavirin
tabl
two
small
uncontrol
clinic
trial
shown
compound
administ
oral
mgkg
day
rash
stage
reduc
sever
symptom
fernandez
earli
studi
certain
carbobenzoxi
tripeptid
carbobenzoxydphelphenitrolarg
norrbi
show
pgml
suffici
inhibit
penetr
measl
viru
new
cell
cell
fusion
haemolyt
properti
viru
also
inhibit
effect
note
viru
adsorpt
one
hundredfold
higher
concentr
show
inhibit
effect
mump
viru
anti
viral
effect
detect
sendai
rsv
possibl
biochem
basi
antivir
action
appreci
time
reevalu
gener
approach
choppin
et
al
highlight
could
interest
point
action
antivir
choppin
et
al
note
similar
ntermin
sequenc
polypeptid
paramyxovirus
mani
short
peptid
shown
earlier
activ
viru
inhibitor
vitro
therefor
propos
fusion
activ
f
protein
might
inhibit
oligopeptid
mimick
region
protein
found
oligopeptid
appropri
amino
acid
sequenc
highli
effect
specif
inhibitor
viru
infect
level
viru
penetr
viru
induc
fusion
haemolysi
ie
activ
reflect
membran
fuse
activ
f
protein
oligopeptid
found
inhibit
sendai
canin
distemp
viru
well
measl
tabl
howev
measl
viru
much
inhibit
virus
studi
sever
conclus
drawn
gener
term
note
oligopeptid
correct
amino
acid
sequenc
specif
inhibitor
longer
peptid
activ
effect
peptid
test
heptapeptid
sequenc
sendai
viru
f
nterminu
effect
concentr
pm
carbobenzoxi
z
group
ntermin
amino
acid
increas
activ
compar
oligopeptid
unblock
ntermin
residu
hydrophob
addit
also
increas
inhibitori
activ
dansyl
dn
tbutyloxicarbonyl
tboc
group
steric
configur
ntermin
phenylalanin
also
significantli
affect
activ
eg
zdphelgli
activ
zlphelphegli
final
esterif
ctermin
amino
acid
decreas
activ
effect
substitut
termini
oligopeptid
may
relat
posit
inhibitor
site
action
thu
carbobenzoxi
dansyl
group
add
hydrophob
nterminu
wherea
esterif
cterminu
decreas
polar
peptid
chang
could
affect
orient
peptid
peptid
may
also
protect
proteolyt
activ
specif
oligopeptid
inhibitor
import
correct
amino
acid
sequenc
demonstr
select
mutant
measl
viru
resist
action
tripeptid
zdphelphel
nojarg
repeat
passag
viru
presenc
peptid
although
mutant
becam
resist
peptid
remain
rel
sensit
zdphelphegli
differ
third
amino
acid
tabl
oligopeptid
appear
signific
toxic
effect
cell
use
studi
cell
surviv
day
detect
cytopath
chang
multipli
normal
presenc
peptid
preliminari
experi
also
suggest
oligopeptid
highli
toxic
mice
howev
problem
compound
rel
insolubl
factor
make
precis
quantit
antivir
effect
difficult
investig
site
action
oligopeptid
synthes
radioact
fluoresc
dansyl
label
monitor
site
bind
radioactivelylabel
oligopeptid
ad
purifi
viru
mock
infect
cell
infect
cell
wash
specif
bind
calcul
studi
suggest
oligopeptid
bind
cell
viru
attenu
measl
vaccin
develop
empir
select
host
rang
mutant
wide
success
use
throughout
world
use
vaccin
countri
may
soon
elimin
measl
endogen
viru
continu
problem
anticip
particularli
adult
virus
reintroduc
visitor
abroad
basic
studi
new
antivir
continu
particularli
oligopeptid
antivir
compound
unlik
extend
use
clinic
except
perhap
tropic
area
diseas
may
life
threaten
howev
vaccin
programm
area
prefer
urgent
need
respiratori
virus
worldwid
distribut
affect
age
group
hamr
et
al
mclean
et
al
parrott
et
al
kapikian
et
al
smorodintsev
chanock
et
al
andrew
et
al
bloom
et
al
kelen
mcleod
tyrrel
et
al
birkumpeterson
featur
epidemiolog
virus
reinfect
common
although
may
often
subclin
subclin
infect
maintain
huge
activ
reservoir
infect
viru
virus
transmit
airborn
droplet
particularli
rapid
spread
note
institution
children
estim
parainfluenza
virus
constitut
one
third
respiratori
tract
infect
human
respiratori
infect
preschool
children
infant
incub
period
vari
day
children
day
adult
preschool
children
particularli
sever
respiratori
infect
often
develop
type
often
associ
laryngo
tracheobronch
croup
wherea
type
iv
caus
infect
lower
respiratori
tract
bronchiti
pneumonia
lower
respiratori
tract
involv
bronchospasm
predomin
clinic
sign
adult
hoars
often
main
symptom
gener
four
viru
type
caus
rang
respiratori
ill
recent
studi
chapel
hill
usa
involv
studi
case
lower
respiratori
tract
infect
pediatr
practic
viru
isol
parainfluenza
respect
summar
children
parainfluenza
viru
type
isol
almost
croup
parainfluenza
type
close
associ
tracheo
bronchiti
risk
hospit
ill
associ
parainfluenza
type
much
less
rsv
risk
infect
former
viru
first
four
month
life
invers
relat
level
neutral
antibodi
measur
cord
serum
birth
interestingli
pattern
antibodi
haemagglutinin
neuramininidas
correl
antibodi
pattern
viral
neutral
assay
abil
assay
detect
rise
antibodi
level
fusion
f
protein
result
serolog
recognit
infect
discern
antibodi
respons
hn
primari
infect
produc
greater
antibodi
rise
hn
f
protein
peak
titr
hn
characterist
delay
month
secondari
infect
parainfluenza
viru
type
infrequ
provid
immunolog
respons
hn
protein
data
suggest
secondari
infect
import
stimul
antibodi
f
protein
case
rise
level
antibodi
f
protein
marker
secondari
infect
virus
typic
paramyxovirus
replic
strategi
similar
alreadi
describ
neg
strand
virus
measl
qv
might
obviou
deduct
comment
natur
reinfect
children
parainfluenza
virus
effect
vaccin
would
difficult
produc
inde
earlier
studi
experiment
vaccin
show
immun
children
later
encount
wild
virul
parainfluenza
viru
could
still
sever
infect
indic
absenc
knowledg
import
antigen
determin
viru
particular
absenc
data
function
fusion
f
glycoprotein
virus
inactiv
measl
rsv
vaccin
experiment
parainfluenza
vaccin
inactiv
process
vaccin
product
probabl
inactiv
f
protein
although
neutral
antibodi
produc
nevertheless
absenc
antibodi
f
protein
immun
children
subsequ
protect
infect
fulgin
et
al
fulgin
et
al
b
describ
vaccin
trial
children
parainfluenza
viru
type
vaccin
prepar
formalin
treatment
viru
harvest
amniot
caviti
embryon
hen
egg
children
immun
rang
age
month
year
antibodi
respons
immun
summar
tabl
gener
satisfactori
sinc
seroneg
children
develop
hi
neutral
antibodi
parainfluenza
viru
infect
occur
commun
month
follow
immun
protect
efficaci
vaccin
assess
evid
protect
could
establish
inde
attack
rate
subsequ
parainfluenza
ill
rather
higher
vaccin
group
control
group
tabl
innov
approach
parainfluenza
type
ill
vaccin
isol
f
hn
glycoprotein
nativ
antigen
form
assembl
multival
structur
review
viru
disrupt
nonion
deterg
octylglucosid
glycoprotein
separ
ultracentrifug
deterg
dialys
glycoprotein
reassembl
pl
control
rsv
control
nonvaccine
pl
tpv
trival
parainfluenza
vaccin
p
parainfluenza
type
amantadin
shown
earlier
studi
davi
et
al
mild
inhibitori
effect
rsv
parainfluenza
type
sendai
viru
although
equival
mark
inhibitori
effect
influenza
chapter
thirti
adult
volunt
given
mg
capsul
amantadin
placebo
twice
daili
day
fourth
day
men
challeng
intranas
parainfluenza
viru
smith
et
al
mild
upper
respiratori
tract
infect
develop
men
differ
number
develop
ill
detect
two
group
also
differ
sever
durat
ill
viru
isol
rate
detect
final
serum
antibodi
titr
differ
two
group
author
conclud
compound
activ
reserv
larg
viru
challeng
dose
use
nevertheless
concentr
drug
detect
nasal
wash
approx
pgml
allow
dilut
would
high
enough
inhibit
replic
parainfluenza
virus
base
vitro
data
although
would
high
enough
inhibit
replic
influenza
virus
vitro
parainfluenza
virus
inhibit
certain
benzimidazol
compound
bucknal
biguanid
also
viru
inhibitori
effect
cell
cultur
tobita
ribavirin
inhibit
sendai
viru
vivo
page
extens
studi
new
antivir
parainfluenza
virus
urgent
requir
could
probabl
initi
good
prospect
success
